Citizens JMP raised the firm’s price target on Protagonist Therapeutics (PTGX) to $102 from $69 and keeps an Outperform rating on the shares. Protagonist Therapeutics has proven it can discover and develop differentiated pipeline candidates and the next wave of candidates are entering the clinic now, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $91 from $74 at Clear Street
- Protagonist Therapeutics Advances Pipeline Amid Financial Loss
- Promising Developments and Strategic Progress at Protagonist Therapeutics Drive Buy Rating
- Protagonist Therapeutics reports Q3 EPS (62c), consensus (64c)
- PTGX Earnings this Week: How Will it Perform?